# Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease

> **NCT07625384** · PHASE3 · NOT_YET_RECRUITING · sponsor: **R-Pharm International, LLC** · enrollment: 52 (estimated)

## Conditions studied

- Still Disease

## Interventions

- **DRUG:** Placebo
- **BIOLOGICAL:** Goflikicept
- **BIOLOGICAL:** Olokizumab

## Key facts

- **NCT ID:** NCT07625384
- **Lead sponsor:** R-Pharm International, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-18
- **Primary completion:** 2027-12-14
- **Final completion:** 2028-07-01
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07625384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07625384, "Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07625384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*